Renal Diseases Drug Development Pipeline Review, 2018

  • ID: 4727289
  • Report
  • 154 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • AdAlta Ltd
  • Boehringer Ingelheim GmbH
  • GenKyoTex SA
  • Kidney Fibrosis
  • Opsidio LLC
  • Scholar Rock Inc
  • MORE

Summary
Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol. There are 58 products in development for this indication.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant. There are 49 products in development for this indication.

Polycystic kidney disease is a disorder in which clusters of cysts develop primarily within the kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in the urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. There are 26 products in development for this indication.

End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant. There are five products in development for this indication.

Molecular targets in development for renal diseases include growth factor receptors, chemokines and kinases. Companies operating in this pipeline space include Angion Biomedica, Prolong Pharmaceuticals and Novartis.

This report “Renal Diseases Drug Development Pipeline Review, 2018”provides an overview of the pipeline landscape for renal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for chronic kidney disease (chronic renal failure), kidney fibrosis, polycystic kidney disease and end-stage kidney disease (end-stage renal disease), and features dormant and discontinued products.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AdAlta Ltd
  • Boehringer Ingelheim GmbH
  • GenKyoTex SA
  • Kidney Fibrosis
  • Opsidio LLC
  • Scholar Rock Inc
  • MORE

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Renal Diseases Report Coverage
2.2 Chronic Kidney Disease (Chronic Renal Failure) - Overview
2.3 Kidney Fibrosis - Overview
2.4 Polycystic Kidney Disease - Overview
2.5 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview

3 Therapeutics Development
3.1 Chronic Kidney Disease (Chronic Renal Failure)
3.2 Kidney Fibrosis
3.3 Polycystic Kidney Disease
3.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

4 Therapeutics Assessment
4.1 Chronic Kidney Disease (Chronic Renal Failure)
4.2 Kidney Fibrosis
4.3 Polycystic Kidney Disease
4.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

5 Companies Involved in Therapeutics Development
5.1 Chronic Kidney Disease (Chronic Renal Failure)
5.2 Kidney Fibrosis
5.3 Polycystic Kidney Disease
5.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

6 Dormant Projects
6.1 Chronic Kidney Disease (Chronic Renal Failure)
6.2 Kidney Fibrosis
6.3 Polycystic Kidney Disease
6.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

7 Discontinued Products
7.1 Chronic Kidney Disease (Chronic Renal Failure)
7.2 Kidney Fibrosis
7.3 Polycystic Kidney Disease
7.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

8 Product Development Milestones
8.1 Chronic Kidney Disease (Chronic Renal Failure)
8.2 Kidney Fibrosis
8.3 Polycystic Kidney Disease

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer

List of Tables
Table 1: Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure)
Table 2: Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure)
Table 3: Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure)
Table 4: Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure)
Table 5: Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure)
Table 6: Number of Products under Development for Kidney Fibrosis
Table 7: Number of Products under Development by Companies, Kidney Fibrosis
Table 8: Number of Products under Development by Universities/Institutes, Kidney Fibrosis
Table 9: Products under Development by Companies, Kidney Fibrosis
Table 10: Products under Development by Universities/Institutes, Kidney Fibrosis
Table 11: Number of Products under Development for Polycystic Kidney Disease, Kidney Fibrosis
Table 12: Number of Products under Development by Companies, Kidney Fibrosis
Table 13: Number of Products under Development by Universities/Institutes, Kidney Fibrosis
Table 14: Products under Development by Companies, Kidney Fibrosis
Table 15: Products under Development by Universities/Institutes, Kidney Fibrosis
Table 16: Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Table 17: Number of Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Table 18: Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Table 19: Number of Products by Stage and Target, Chronic Kidney Disease (Chronic Renal Failure)
Table 20: Number of Products by Stage and Mechanism of Action, Chronic Kidney Disease (Chronic Renal Failure)
Table 21: Number of Products by Stage and Route of Administration, Chronic Kidney Disease (Chronic Renal Failure)
Table 22: Number of Products by Stage and Molecule Type, Chronic Kidney Disease (Chronic Renal Failure)
Table 23: Number of Products by Stage and Target, Kidney Fibrosis
Table 24: Number of Products by Stage and Mechanism of Action, Kidney Fibrosis
Table 25: Number of Products by Stage and Route of Administration, Kidney Fibrosis
Table 26: Number of Products by Stage and Molecule Type, Kidney Fibrosis
Table 27: Number of Products by Stage and Target, Polycystic Kidney Disease
Table 28: Number of Products by Stage and Mechanism of Action, Polycystic Kidney Disease
Table 29: Number of Products by Stage and Route of Administration, Polycystic Kidney Disease
Table 30: Number of Products by Stage and Molecule Type, Polycystic Kidney Disease
Table 31: Number of Products by Stage and Target, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Table 32: Number of Products by Stage and Mechanism of Action, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Table 33: Number of Products by Stage and Route of Administration, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Table 34: Number of Products by Stage and Molecule Type, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Table 35: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Allena Pharmaceuticals Inc
Table 36: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp
Table 37: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH
Table 38: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Arch Biopartners Inc
Table 39: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc
Table 40: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc
Table 41: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG
Table 42: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim GmbH
Table 43: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd
Table 44: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Ltd
Table 45: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Corvidia Therapeutics Inc
Table 46: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DiaMedica Therapeutics Inc
Table 47: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Dimerix Bioscience Pty Ltd
Table 48: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DURECT Corp
Table 49: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG
Table 50: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd
Table 51: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by KBP BioSciences Co Ltd
Table 52: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Klotho Therapeutics Inc
Table 53: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nash Pharmaceuticals Inc
Table 54: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG
Table 55: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health Inc
Table 56: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Opsidio LLC

List of Figures
Figure 1: Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure)
Figure 2: Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure)
Figure 3: Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure)
Figure 4: Number of Products under Development for Kidney Fibrosis
Figure 5: Number of Products under Development by Companies, Kidney Fibrosis
Figure 6: Number of Products under Development for Polycystic Kidney Disease, Kidney Fibrosis
Figure 7: Number of Products under Development by Companies, Kidney Fibrosis
Figure 8: Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Figure 9: Number of Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Figure 10: Number of Products by Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure)
Figure 11: Number of Products by Stage and Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure)
Figure 12: Number of Products by Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure)
Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure)
Figure 14: Number of Products by Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure)
Figure 15: Number of Products by Stage and Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure)
Figure 16: Number of Products by Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure)
Figure 17: Number of Products by Stage and Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure)
Figure 18: Number of Products by Top 10 Targets, Kidney Fibrosis
Figure 19: Number of Products by Stage and Top 10 Targets, Kidney Fibrosis
Figure 20: Number of Products by Top 10 Mechanism of Actions, Kidney Fibrosis
Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Fibrosis
Figure 22: Number of Products by Stage and Routes of Administration, Kidney Fibrosis
Figure 23: Number of Products by Top 10 Molecule Types, Kidney Fibrosis
Figure 24: Number of Products by Stage and Top 10 Molecule Types, Kidney Fibrosis
Figure 25: Number of Products by Top 10 Targets, Polycystic Kidney Disease
Figure 26: Number of Products by Stage and Top 10 Targets, Polycystic Kidney Disease
Figure 27: Number of Products by Top 10 Mechanism of Actions, Polycystic Kidney Disease
Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions, Polycystic Kidney Disease
Figure 29: Number of Products by Routes of Administration, Polycystic Kidney Disease
Figure 30: Number of Products by Stage and Routes of Administration, Polycystic Kidney Disease
Figure 31: Number of Products by Molecule Types, Polycystic Kidney Disease
Figure 32: Number of Products by Stage and Molecule Types, Polycystic Kidney Disease
Figure 33: Number of Products by Targets, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Figure 34: Number of Products by Stage and Targets, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Figure 35: Number of Products by Mechanism of Actions, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Figure 36: Number of Products by Stage and Mechanism of Actions, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Figure 37: Number of Products by Molecule Types, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Figure 38: Number of Products by Stage and Molecule Types, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AdAlta Ltd
  • Allena Pharmaceuticals Inc
  • apceth Biopharma GmbH
  • Arch Biopartners Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • BiOrion Technologies BV
  • Boehringer Ingelheim GmbH
  • Boryung Pharmaceutical Co Ltd
  • Celgene Corp
  • Certa Therapeutics Pty Ltd
  • Conatus Pharmaceuticals Inc
  • Corvidia Therapeutics Inc
  • DiaMedica Therapeutics Inc
  • Dimerix Bioscience Pty Ltd
  • DiscoveryBiomed Inc
  • DURECT Corp
  • Epigen Biosciences Inc
  • Galectin Therapeutics Inc
  • GenKyoTex SA
  • GNI Group Ltd
  • iBio Inc
  • IC-MedTech Inc
  • Ipsen SA
  • Isarna Therapeutics GmbH
  • KBP BioSciences Co Ltd
  • Kidney Fibrosis
  • Klotho Therapeutics Inc
  • Les Laboratoires Servier SAS
  • ManRos Therapeutics
  • Mironid Ltd
  • NovaTarg Therapeutics Inc
  • Novo Nordisk AS
  • OPKO Health Inc
  • Opsidio LLC
  • Otsuka Holdings Co Ltd
  • Pharmaxis Ltd
  • Q BioMed Inc
  • Redx Pharma Plc
  • Regulus Therapeutics Inc
  • Resverlogix Corp
  • Sanwa Kagaku Kenkyusho Co Ltd
  • Sarfez Pharmaceuticals Inc
  • Scholar Rock Inc
  • Sirnaomics Inc
  • Sphaera Pharma Pte Ltd
  • Symic Biomedical Inc
  • Taisho Pharmaceutical Holdings Co Ltd
  • Theravance Biopharma Inc
  • Unity Biotechnology Inc
  • Vascular Biogenics Ltd
  • Vascular BioSciences
  • VESSL Therapeutics Ltd
  • Vicore Pharma AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll